Aminocaproic acid

drugbox
IUPAC_name = 6-aminohexanoic acid

---

CAS_number = 60-32-2
ATC_prefix = B02
ATC_suffix = AA01
ATC_supplemental =
PubChem = 564
DrugBank = APRD00791
C=6 | H=13 | N=1 | O=2
molecular_weight = 131.173 g/mol
bioavailability =
protein_bound =
metabolism = Renal
elimination_half-life = 2 hours
pregnancy_category =
legal_status =
routes_of_administration =

Aminocaproic acid (also known as Amicar, є-amino caproic acid, or 6-aminohexanoic acid) is a derivative and analogue of the amino acid lysine, which makes it an effective inhibitor for enzymes which bind that particular residue. Such enzymes include proteolytic enzymes like plasmin, the enzyme responsible for fibrinolysis. For this reason it is effective in treatment of some bleeding disorders and is marketed as Amicar.

Mechanism of action

Aminocaproic acid works as an anti-fibrinolytic or anti-proteolytic. As a lysine analogue, it binds reversibly to the kringle domain of the enzymogen plasminogen.Thus plasminogen can not be activated (by its activators) to plasmin, which then can not split fibrin (anti-fibrinolytic effect).

Clinical use

Aminocaproic acid is used to treat excessive postoperative bleeding. It can be given orally or intravenously. One scenario where it may be useful is to treat bleeding after dental extractions in patients with hemophilia, because the oral mucosa is rich in plasminogen activators. A meta-analysis found that lysine analogs like aminocaproic acid significantly reduced blood loss in patients undergoing coronary artery bypass grafting.Fact|date=June 2007

ide effects

Its side effects are mainly related to the gastrointestinal tract and include nausea, vomiting, abdominal pain, and diarrhea. It may cause generalised myalgia. The main risk associated with aminocaproic acid is the increased risk for thrombosis because of the inhibition of fibrinolysis.

Other uses

Aminocaproic acid is occasionally used in BN-PAGE buffers, not for its effects as a proteolysis inhibitor, but to solubilize membrane proteins in place of sodium chloride (which is incompatible with PAGE in the necessary concentration). Percent recovery of protein complexes increases linearly with the concentration of inhibitor (between 125 mM and 750 mM) [Schägger, H and Von Jagow, G (1991). Blue Native Electrophoresis for Isolation of Membrane Protein Complexes in Enzymatically Active Form. "Analytical Biochemistry 199" (2): 223-231.] .

References